Published in Healthcare Mergers, Acquisitions and Ventures Week, February 17th, 2007
MER 103 is an enteric-coated tablet of alendronate and GIPET, Merrion's proprietary platform technology, which increases drug absorption. The study confirmed several important improvements for patient convenience and compliance relating to the administration of alendronate, the leading bisphosphonate for the prevention and treatment of osteoporosis, marketed as Fosamax (Merck).
The study was conducted in postmenopausal women and compared the absorption of a 6...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.